Metastatic breast cancer Trials in St. Louis, United States
Conditions / Metastatic breast cancer / St. Louis, United States
Metastatic breast cancer has been the subject of sustained clinical investigation across multiple research sites.
41 total trials for this combination
Showing top 10 of 41 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | RECRUITING | — |
| NCT02163694 | A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | COMPLETED | PHASE3 |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | RECRUITING | PHASE1/PHASE2 |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | RECRUITING | PHASE3 |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | COMPLETED | NA |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | RECRUITING | PHASE1 |
| NCT01492101 | The BEACON Study (Breast Cancer Outcomes With NKTR-102) | COMPLETED | PHASE3 |
| NCT05216432 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | RECRUITING | PHASE1 |
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) | COMPLETED | PHASE2/PHASE3 |